Danielle Nance, MD
Hematology · Gilbert, AZNPI 1689718264
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $59,185 of the $86,032 with a category attached, or 68.8%. 22 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 28.2% of the total. Reporting peaked in 2021 at $20,864 and has fallen 74.1% since, to $5,397 in 2025.
Across 108 payments — averaging $796.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$24K
- HEMA Biologics, LLC$13K
- CSL Behring$12K
- Bayer$10K
- Sanofi$10K
- Aptevo Therapeutics Inc$6K
- plus $12K from 16 others
Across 77 payments — averaging $1323.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$45K
- Alnylam Pharmaceuticals Inc.$36K
- Sanofi US Services Inc.$21K
What the payments were for
- Consulting fees$59,18569%
- Speaking & faculty fees$19,49923%
- Travel & lodging$3,7114%
- Food & beverage$3,1824%
- Education$4431%
- Gifts$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 17 | $24,243 |
| HEMA Biologics, LLC | 22 | $13,042 |
| CSL Behring | 14 | $11,506 |
| Bayer | 18 | $9,787 |
| Sanofi | 7 | $9,662 |
| Aptevo Therapeutics Inc | 6 | $5,713 |
| Spark Therapeutics, Inc. | 5 | $3,954 |
| Pfizer | 2 | $2,535 |
| Medexus Pharma, Inc. | 2 | $2,500 |
| Novartis | 1 | $2,025 |
| Incyte Corporation | 2 | $180 |
| AstraZeneca | 1 | $128 |
| Amgen | 1 | $122 |
| Gilead | 1 | $122 |
| Bioverativ Therapeutics Inc. | 1 | $97 |
| Octapharma USA, Inc. | 1 | $97 |
| Genentech USA, Inc. | 1 | $95 |
| Dova Pharmaceuticals | 1 | $95 |
| Genentech, Inc. | 1 | $50 |
| Novo Nordisk | 2 | $37 |
| Agios Pharmaceuticals, Inc. | 1 | $26 |
| AbbVie | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdzynmaAdamts13, Recombinant-Krhn | 26 | $928,452 |
| OxbrytaVoxelotor | 32 | $412,572 |
| DopteletAvatrombopag Maleate | 17 | $354,701 |
| JakafiRuxolitinib Phosphate | 22 | $273,627 |
| EliquisApixaban | 201 | $202,522 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $87,024 |
| PromactaEltrombopag Olamine | 11 | $77,558 |
| XareltoRivaroxaban | 57 | $66,548 |
| CreonLipase/Protease/Amylase | 18 | $41,805 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 28 | $39,239 |
| Enoxaparin Sodium | 21 | $20,403 |
| OxycontinOxycodone Hcl | 12 | $7,205 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 23 | $2,548 |
| Hydroxyurea | 52 | $1,289 |
| Fluconazole | 31 | $736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dova PharmaceuticalsDoptelet | $95 | $354,70117 claims |
| Incyte CorporationJakafi | $180 | $273,62722 claims |
| PfizerEliquis | $2,535 | $202,522201 claims |
| CSL BehringHizentra | $11,506 | $87,02413 claims |
| NovartisPromacta | $2,025 | $77,55811 claims |
| AbbVieCreon | $16 | $41,80518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other hematology in Gilbert
- Pedro Camacho MaldonadoGilbert$469
- Joseph MikhaelScottsdale$1.5M
- Rafael FonsecaScottsdale$650K
- John PawloskiPhoenix$246K
- Pierre NoelScottsdale$51K
- Abdullah LadhaScottsdale$17K
- Misam ZawitGoodyear$11K
- Abdulrahman AbonofalGoodyear$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.